A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

October 11, 2022

Primary Completion Date

February 16, 2024

Study Completion Date

February 16, 2024

Conditions
Uterine Fibroids (MeSH Heading: Leiomyoma)
Interventions
DRUG

KLH-2109

Oral administration

DRUG

Placebo

Oral administration

Trial Locations (1)

Unknown

Clinical Research Site, Multiple Locations

All Listed Sponsors
lead

Kissei Pharmaceutical Co., Ltd.

INDUSTRY